Orthologous mammalian APOBEC3A cytidine deaminases hypermutate nuclear DNA

Molecular Biology and Evolution

Volumn 31, Issue 2, 2014, Pages 330-340

  Caval, Vincent ^a   Suspène, Rodolphe ^a   Vartanian, Jean Pierre ^a   Wain Hobson, Simon ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

APOBEC3; cytidine deaminase; double strand breaks; hypermutation; methylcytidine; nuclear DNA

Indexed keywords

CELL NUCLEUS DNA; CYTIDINE DEAMINASE; MITOCHONDRIAL DNA;

ANIMAL CELL; APOBEC3A GENE; ARTICLE; CALLITRICHINAE; CATABOLISM; CONTROLLED STUDY; DNA STRAND BREAKAGE; DOG; GENE; GENE CLUSTER; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENOMIC INSTABILITY; HAPLORHINI; HORSE; HOST CELL; HUMAN; HUMAN CELL; NONHUMAN; RHESUS MONKEY; SHEEP; SOMATIC HYPERMUTATION;

APOBEC3; CYTIDINE DEAMINASE; DOUBLE-STRAND BREAKS; HYPERMUTATION; METHYLCYTIDINE; NUCLEAR DNA;

AMINO ACID SEQUENCE; ANIMALS; CYTIDINE; CYTIDINE DEAMINASE; DEAMINATION; DNA; DNA BREAKS, DOUBLE-STRANDED; DOGS; GENOMIC INSTABILITY; HEK293 CELLS; HELA CELLS; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; MAMMALS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PHYLOGENY; PROTEIN STRUCTURE, SECONDARY; PROTEINS; SEQUENCE ALIGNMENT;

EID: 84893046074     PISSN: 07374038     EISSN: 15371719     Source Type: Journal    
DOI: 10.1093/molbev/mst195     Document Type: Article

References (55)

1. Argyris EG, Acheampong E, Wang F, Huang J, Chen K, Mukhtar M, Zhang H. 2007. The interferon-induced expression of APOBEC3G in human blood-brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system. Virology 367:440-451.
2. Aynaud MM, Suspène R, Vidalain PO, Mussil B, Guetard D, Tangy F, Wain-Hobson S, Vartanian JP. 2012. Human Tribbles 3 protects nuclear DNA from cytidine deamination by APOBEC3A. J Biol Chem. 287:39182-39192.
3. Bininda-Emonds OR, Cardillo M, Jones KE, MacPhee RD, Beck RM, Grenyer R, Price SA, Vos RA, Gittleman JL, Purvis A. 2007. The delayed rise of present-day mammals. Nature 446:507-512.
4. Bogerd HP, Wiegand HL, Hulme AE, Garcia-Perez JL, O'Shea KS, Moran JV, Cullen BR. 2006. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc Natl Acad Sci USA. 103:8780-8785.
5. Bonvin M, Achermann F, Greeve I, et al. (11 co-authors). 2006. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 43:1364-1374.
6. Bulliard Y, Narvaiza I, Bertero A, et al. (13 co-authors). 2011. Structurefunction analyses point to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities. J Virol. 85:1765-1776.
7. Burns MB, Lackey L, Carpenter MA, et al. (17 co-authors). 2013. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494:366-370.
8. Carpenter MA, Li M, Rathore A, et al. (12 co-authors). 2012. Methylcytosine and normal cytosine deamination by the foreign DNA restriction enzyme APOBEC3A. J Biol Chem. 287:34801-34808.
9. Chen H, Lilley CE, Yu Q, Lee DV, Chou J, Narvaiza I, Landau NR, Weitzman MD. 2006. APOBEC3A is a potent inhibitor of adenoassociated virus and retrotransposons. Curr Biol. 16:480-485.
10. Conticello SG, Harris RS, Neuberger MS. 2003. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol. 13:2009-2013.
11. Conticello SG, Thomas CJ, Petersen-Mahrt SK, Neuberger MS. 2005. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol Biol Evol. 22:367-377.
12. Dang Y, Abudu A, Son S, Harjes E, Spearman P, Matsuo H, Zheng YH. 2011. Identification of a single amino acid required for APOBEC3 antiretroviral cytidine deaminase activity. J Virol. 85:5691-5695.
13. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809.
14. Henry M, Guetard D, Suspene R, Rusniok C, Wain-Hobson S, Vartanian JP. 2009. Genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3G. PLoS One 4:e4277.
15. Henry M, Terzian C, Peeters M, Wain-Hobson S, Vartanian JP. 2012. Evolution of the primate APOBEC3A cytidine deaminase gene and identification of related coding regions. PLoS One 7:e30036.
16. Hultquist JF, Lengyel JA, Refsland EW, Larue RS, Lackey L, Brown WL, Harris RS. 2011. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol. 84:11220-112234.
17. Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, Scott J, Navaratnam N. 2002. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79: 285-296.
18. Jones PA, Baylin SB. 2007. The epigenomics of cancer. Cell 128:683-692.
19. Kaina B. 2003. DNA damage-triggered apoptosis: critical role of DNA repair, double-strand breaks, cell proliferation and signaling. Biochem Pharmacol. 66:1547-1554.
20. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, Malim MH. 2009. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol. 83:9474-9485.
21. Landry S, Narvaiza I, Linfesty DC, Weitzman MD. 2011. APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. EMBO Rep. 12:444-450.
22. Larue RS, Andresdottir V, Blanchard Y, et al. (20 co-authors). 2008. Guidelines for naming non-primate APOBEC3 genes and proteins. J Virol. 83:494-497.
23. LaRue RS, Jonsson SR, Silverstein KA, Lajoie M, Bertrand D, El-Mabrouk N, Hotzel I, Andresdottir V, Smith TP, Harris RS. 2008. The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multifunctional domain organization that existed in the ancestor of placental mammals. BMC Mol Biol. 9:104.
24. Lecossier D, Bouchonnet F, Clavel F, Hance AJ. 2003. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300:1112.
25. Long J, Delahanty RJ, Li G, et al. (13 co-authors). 2013. A common deletion in the APOBEC3 genes and breast cancer risk. J Natl Cancer Inst. 105:573-579.
26. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. 2003. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99-103.
27. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR. 2003. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114:21-31.
28. MarinM, Rose KM, Kozak SL, Kabat D. 2003. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. NatMed. 9: 1398-1403.
29. Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, Morisawa T, Azuma T, Okazaki IM, Honjo T, Chiba T. 2007. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med. 13:470-476.
30. Muckenfuss H, Hamdorf M, Held U, Perkovic M, Lower J, Cichutek K, Flory E, Schumann GG, Munk C. 2006. APOBEC3 proteins inhibit human LINE-1 retrotransposition. J Biol Chem. 281:22161-22172.
31. Munk C, Beck T, Zielonka J, et al. (13 co-authors). 2008. Functions, structure, and read-through alternative splicing of feline APOBEC3 genes. Genome Biol. 9:R48.
32. Munk C, Willemsen A, Bravo IG. 2012. An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. BMC Evol Biol. 12:71.
33. Mussil B, Suspène R, Aynaud M-M, Gauvrit A, Vartanian J-P, Wain-Hobson S. 2013. Human APOBEC3A isoforms translocate to the nucleus and induce DNA double strand breaks leading to cell stress and death. PLoS One 8:e73641.
34. Nik-Zainal S, Alexandrov LB, Wedge DC, et al. (53 co-authors). 2012. Mutational processes molding the genomes of 21 breast cancers. Cell 149:979-993.
35. Okazaki IM, Hiai H, Kakazu N, Yamada S, Muramatsu M, Kinoshita K, Honjo T. 2003. Constitutive expression of AID leads to tumorigenesis. J Exp Med. 197:1173-1181.
36. Petit V, Guétard D, Renard M, Keriel A, Sitbon M, Wain-Hobson S, Vartanian JP. 2009. Murine APOBEC1 is a powerful mutator of retroviral and cellular RNA in vitro and in vivo. J Mol Biol. 385: 65-78.
37. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, Harris RS. 2010. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38:4274-4284.
38. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. 1998. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 273:5858-5868.
39. Schmitt K, Guo K, Algaier M, Ruiz A, Cheng F, Qiu J, Wissing S, Santiago ML, Stephens EB. 2011. Differential virus restriction patterns of rhesus macaque and human APOBEC3A: implications for lentivirus evolution. Virology 419:24-42.
40. Sheehy AM, Gaddis NC, Choi JD,Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.
41. Sheehy AM, Gaddis NC, Malim MH. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med. 9:1404-1407.
42. Shinohara M, Io K, Shindo K, Matsui M, Sakamoto T, Tada K, Kobayashi M, Kadowaki N, Takaori-Kondo A. 2012. APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Sci Rep. 2:806.
43. Stenglein MD, Burns MB, Li M, Lengyel J, Harris RS. 2010. APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol. 17:222-229.
44. Suspène R, Aynaud MM, Guétard D, Henry M, Eckhoff G, Marchio A, Pineau P, Dejean A, Vartanian JP, Wain-Hobson S. 2011. Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism. Proc Natl Acad Sci USA. 108:4858-4863.
45. Suspène R, Aynaud MM, Koch S, Pasdeloup D, Labetoulle M, Gaertner B, Vartanian JP, Meyerhans A,Wain-Hobson S. 2011. Genetic editing of herpes simplex virus 1 and Epstein-Barr herpesvirus genomes by human APOBEC3 cytidine deaminases in culture and in vivo. J Virol. 85:7594-7602.
46. Suspène R, Aynaud M-M, Vartanian J-P, Wain-Hobson S. 2013. Efficient deamination of 5-methylcytidine and 5-substituted cytidine residues in DNA by human APOBEC3A cytidine deaminase. PLoS One 8: e63461.
47. Suspène R, Guétard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP. 2005. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci USA. 102:8321-8326.
48. Suspène R, Henry M, Guillot S, Wain-Hobson S, Vartanian JP. 2005. Recovery of APOBEC3-edited human immunodeficiency virus G-A hypermutants by differential DNA denaturation PCR. J Gen Virol. 86:125-129.
49. Thielen BK,McNevin JP,McElrathMJ, Hunt BV, Klein KC, Lingappa JR. 2010. Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J Biol Chem. 285:27753-27766.
50. Vartanian JP, Guétard D, Henry M, Wain-Hobson S. 2008. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science 320: 230-233.
51. Vartanian JP, Henry M, Marchio A, et al. (12 co-authors). 2010. Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog. 6:e1000928.
52. Wijesinghe P, Bhagwat AS. 2012. Efficient deamination of 5-methylcytosines in DNA by human APOBEC3A, but not by AID or APOBEC3G. Nucleic Acids Res. 40:9206-9217.
53. Yamanaka S, Balestra ME, Ferrell LD, Fan J, Arnold KS, Taylor S, Taylor JM, Innerarity TL. 1995. Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc Natl Acad Sci USA. 92:8483-8487.
54. Zhang T, Cai J, Chang J, et al. (13 co-authors). 2012. Evidence of associations of APOBEC3B gene deletion with susceptibility to persistent HBV infection and hepatocellular carcinoma. Hum Mol Genet. 22: 1262-1269.
55. Zielonka J, Bravo IG, Marino D, Conrad E, Perkovic M, Battenberg M, Cichutek K, Munk C. 2009. Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases. J Virol. 83: 7547-7559.